AstraZeneca has asked the Supreme Court to hear its case challenging the Medicare Drug Price Negotiation Program created through the Inflation Reduction Act (IRA).

According to the Supreme Court's docket, AstraZeneca's petition was filed on Sept. 19. The company has asked the court to consider "whether the IRA implicates an interest of pharmaceutical manufacturers that is protected by the Due Process Clause."

In the first selection of drugs for Medicare negotiation, AstraZeneca's diabetes medication Farxiga was selected. In the following round of drugs, its mantle cell lymphoma treatment Calquence was also chosen.

In its petition, AstraZeneca noted the looming deadline it faces. On Jan. 1, the........

© The Hill